Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

European Radiology

Volumn 23, Issue 2, 2013, Pages 570-578

  Derlin, Thorsten ^a   Peldschus, Kersten ^a   Münster, Silvia ^a   Bannas, Peter ^a   Herrmann, Jochen ^a   Stübig, Thomas ^a   Habermann, Christian R ^a   Adam, Gerhard ^a   Kröger, Nicolaus ^a   Weber, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Myeloma; PET CT; Response assessment; Stem cell transplantation; Whole body MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MALE; MULTIPLE MYELOMA; PET SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE BODY MRI;

EID: 84878609750     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2600-5     Document Type: Article

References (24)

1. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336:1657-1664
2. Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875-887
3. Kroger N (2007) Mini-midi-maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 21:1851-1858
4. Zamagni E, Patriarca F, Nanni C, et al. (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989-5995
5. Durie BG, Harousseau JL, Miguel JS, et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473
6. Derlin T, Weber C, Habermann CR, et al. (2012) 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging 39:493-500
7. Lin C, Luciani A, Belhadj K, et al. (2010) Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 254:521-531
8. Blade J, Samson D, Reece D, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123
9. Durie BG, Waxman AD, D'Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43:1457-1463
10. Bartel TB, Haessler J, Brown TL, et al. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 11:2068-2076
11. Nanni C, Zamagni E, Farsad M, et al. (2006) Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 33:525-531
12. Durie BG (2006) The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 42:1539-1543
13. Becherer A, De Santis M, Karanikas G, et al. (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54:284-288
14. Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994
15. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55:56-63
16. Fonti R, Salvatore B, Quarantelli M, et al. (2008) 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 49:195-200
17. Zamagni E, Nanni C, Patriarca F, et al. (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50-55
18. Bauerle T, Hillengass J, Fechtner K, et al. (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 252:477-485
19. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
20. Dimopoulos M, Terpos E, Comenzo RL, et al. (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23:1545-1556
21. Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A (2011) A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 38:1158-1170
22. Shortt CP, Gleeson TG, Breen KA, et al. (2009) Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 192:980-986
23. Paiva B, Vidriales MB, Cervero J, et al. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-4023
24. Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M (2011) Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 196:W790-W795